Single nucleotide polymorphism

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population

M. Zhang, Yang, Y., Zhao, G., Di, X., Xu, L., Jiang, N., Xu, J., and Xu, X., Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population, vol. 13, pp. 831-837, 2014.

The aim of this study was to investigate the effect of the CYP2C9*3 (CYP2C9 1075 A>C) polymorphism on meloxicam pharmacokinetics in a Chinese population. Twenty-four healthy volunteers were enrolled in this study. The pyrosequencing technique was used to identify polymorphisms of CYP2C9. The concentration of meloxicam in plasma was determined by a high-performance liquid chromatography assay with mass spectrographic analysis. The Drug and Statistics Software (DAS, version 2.0) was used for curve fitting and calculations of pharmacokinetic parameters.

Subscribe to Single nucleotide polymorphism